Nasdaq
$12.60▼ 2.02%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.63BShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 9.9After-hours26.09.10 08:294Ownership#●●●
Kailera Therapeutics, Inc.
Insider Nicholson Nur filed a Form 4 statement regarding changes in beneficial ownership of securities for Kailera Therapeutics, Inc. on September 7, 2026.…more
$12.60-2.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.9After-hours26.09.10 08:233Ownership
Kailera Therapeutics, Inc.
Kailera Therapeutics has filed a Power of Attorney authorizing designated individuals to execute and file SEC reports, including Schedules 13D/13G and Forms 3, 4, and 5, on behalf of the undersigned. This filing serves as an administrative measure to ensure compliance with reporting requirements for securities transactions.…more
$12.60-2.02%vs prev closeView filingShare - 8.12After-hours26.08.13 05:2910-QEarnings
Kailera Therapeutics, Inc.
As of August 6, 2026, Kailera Therapeutics, Inc. had 129,643,676 shares of common stock outstanding. The company entered into new amended employment agreements with its key executives, including the CEO, COO, and CCO, effective as of April 2026. This 10-Q filing provides an update on the company's financial position and formalizes executive compensation structures.…more
$12.60-2.02%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.1Pre-market26.10.01 19:45#●●●#●●●
Kailera Therapeutics Presents New Clinical Data at EASD 2026
Kailera Therapeutics presented positive Phase 1 clinical data for its obesity treatment candidates at the EASD Annual Meeting. The company and its partner, Hengrui Pharma, showcased clinical evidence supporting the efficacy and safety of their GLP-1 based pipeline.…more
$12.60-2.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.30Pre-market26.09.30 20:00
●●●●●●●● ●●●●● ●●●●●●
Kailera Therapeutics has finished patient enrollment for its global Phase 3 clinical trials of the obesity drug candidate ribupatide. The company expects to report topline data in mid-2028, marking a milestone in its ongoing clinical development process.…more
$12.60-2.02%vs prev close - 9.16Pre-market26.09.16 20:00
●●●●●●●● ●●●●● ●●●●●●
Kailera Therapeutics announced its participation in upcoming investor conferences scheduled for September. Company executives will present updates on their obesity care product pipeline and business strategy.…more
$12.60-2.02%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report